申请人:Merck Frosst Canada Inc.
公开号:US04609744A1
公开(公告)日:1986-09-02
Compounds of the Formula I: ##STR1## and pharmaceutically acceptable salts thereof are leukotriene antagonists. These compounds inhibit SRS-A and leukotriene synthesis and are antagonists of SRS-A and are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.
化合物I的结构如下:##STR1##及其药用盐是白三烯拮抗剂。这些化合物抑制SRS-A和白三烯的合成,是SRS-A的拮抗剂,因此在治疗哮喘、过敏性疾病、炎症、皮肤疾病和某些心血管疾病中具有用途。